Tomoaki Hakariya1, Shiro Obata2, Tsukasa Igawa3, Hideki Sakai3. 1. Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan erbb2jp@yahoo.co.jp. 2. Department of Radiology and Radiotherapy, Nagasaki prefecture Shimabara Hospital, Nagasaki, Japan. 3. Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Abstract
AIM: We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy. PATIENTS AND METHODS: Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively. RESULTS: A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT. CONCLUSION: SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control. Copyright
AIM: We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy. PATIENTS AND METHODS: Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively. RESULTS: A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT. CONCLUSION: SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control. Copyright
Authors: Wang Lan; Liu Lihong; Han Chun; Liu Shutang; Wang Qi; Xu Liang; Li Xiaoning; Liu Likun Journal: Strahlenther Onkol Date: 2022-01-14 Impact factor: 4.033